Upnar integration execution risk
Management acknowledged it is 'too early to say' on margin expansion from the Upnar acquisition, with optimal utilization required. Only 75% stake completed as of Q3 with balance 25% expected by Q2 FY27.
SENORES / Q3-FY26 / risks
Keep the risk register visible.
Senores Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
EBITDA margin sustainability in regulated markets
US regulated market EBITDA margins at 40% are below the previous peak of 44%, which management attributed to product mix. The shift towards more own-products (vs CDMO) is expected to restore margins by 1%, but analyst questioned whether peak margins can be surpassed.
Promoter pledge and warrant dilution
Recent promoter share pledge and warrant issuance raised concerns about capital structure. Management explained ₹75-100 crore may be needed for working capital and product acquisitions over 12 months, with warrants structured for 25% upfront contribution.
Working capital intensity
Net working capital cycle at 90-94 days could strain as rapid 50%+ growth continues. Purchase of stock-in-trade increased significantly from ₹11 crore to ₹37 crore sequentially due to CMO outsourcing strategy.